Measuring medication adherence in patients with incident hypertension: a retrospective cohort study

Karen L Tang, Hude Quan, Doreen M Rabi, Karen L Tang, Hude Quan, Doreen M Rabi

Abstract

Background: Though pharmacy claims data are commonly used to study medication adherence, there remains no standard operational definition for adherence especially for patients on multiple medications. Even when studies use the same terminology, the actual methods of calculating adherence can differ drastically. It is unclear whether the use of different definitions results in different conclusions regarding adherence and associated outcomes. The objective of our study was to compare adherence rates and associations with mortality using different operational definitions of adherence, and using various methods of handling concurrent medication use.

Methods: We conducted a cohort study of patients aged ≥65 years from Manitoba, Canada, with incident hypertension diagnosed in 2004 and followed to 2009. We calculated adherence rates to anti-hypertensive medications using different operational definitions of medication adherence (including interval and prescription based medication possession ratios [MPR] and proportion of days covered [PDC]). For those on concurrent medications, we calculated adherence rates using the different methods of handling concurrent medication use, for each definition. We used logistic regression to determine the association between adherence and mortality for each operational definition.

Results: Among 2199 patients, 24.1% to 90.5% and 71.2% to 92.7% were considered adherent when using fixed interval and prescription-based interval medication possession ratios [MPRi and MPRp] respectively, depending on how concurrent medications were handled. Adherence was inversely associated with death, with the strongest association for MPRp measures. This association was significant only when considering adherence to any anti-hypertensive [aOR 0.70, 95% CI 0.51, 0.97], or when the mean of the class-specific MPRp's [adjusted OR 0.71, 95% CI 0.53, 0.95] was used. No significant association existed when the highest or lowest class-specific MPRp was used as the adherence estimate.

Conclusion: The range of adherence estimates varies widely depending on the operational definition used. Given less variation in adherence rates and their stronger association against mortality, we recommend using prescription-based MPR's to define medication adherence.

Keywords: Adherence; Claims data; Drug Utilization; Hypertension; Prescription Drugs.

References

    1. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–574. doi: 10.1002/pds.1230.
    1. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. doi: 10.1111/j.1524-4733.2007.00213.x.
    1. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54(Suppl 1):S57–60. doi: 10.1016/S0895-4356(01)00457-7.
    1. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530. doi: 10.1097/.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100.
    1. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87. doi: 10.1111/j.1742-1241.2007.01630.x.
    1. Sattler EL, Lee JS. Perri M, 3rd. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383–399. doi: 10.1007/s40266-013-0074-z.
    1. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457–464.
    1. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44. doi: 10.1345/aph.1K671.
    1. Health Canada. Federal Public Drug Benefit Programs. October 1, 2004; . Accessed 8 2014.
    1. Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54(6):1423–1428. doi: 10.1161/HYPERTENSIONAHA.109.139279.
    1. Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. Can Med Assoc J. 2012;184(1):E49–E56. doi: 10.1503/cmaj.101863.
    1. Shin S, Song H, Oh SK, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36(11):1000–1005. doi: 10.1038/hr.2013.85.
    1. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149–2153. doi: 10.2337/diacare.27.9.2149.
    1. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54–65. doi: 10.3121/cmr.2013.1113.
    1. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065–2076. doi: 10.1185/03007995.2010.494462.
    1. Levesque A, Li HZ, Pahal JS. Factors related to patients’ adherence to medication and lifestyle change recommendations: Data from Canada. International Journal of Psychological Studies. 2012;4(2):42. doi: 10.5539/ijps.v4n2p42.
    1. Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011;34(2):338–340. doi: 10.2337/dc10-1779.
    1. Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. Ann Behav Med. 2010;40(2):228–233. doi: 10.1007/s12160-010-9212-6.
    1. Halava H, Korhonen MJ, Huupponen R, et al. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ. 2014;186(12):E449–456. doi: 10.1503/cmaj.131807.
    1. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–516. doi: 10.2147/PPA.S40736.
    1. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46(11):1125–1133. doi: 10.1097/MLR.0b013e31817924d2.
    1. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;4
    1. Hansen RA, Voils CI, Farley JF, et al. Prescriber Continuity and Medication Adherence for Complex Patients. Ann Pharmacother. 2015;49(3):293–302. doi: 10.1177/1060028014563266.
    1. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):59–66.
    1. Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008;117(22):2884–2892. doi: 10.1161/CIRCULATIONAHA.107.724104.
    1. Baggarly SA, Kemp RJ, Wang X, Magoun AD. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Res Social Adm Pharm. 2014;10(6):e99–e112. doi: 10.1016/j.sapharm.2014.02.002.
    1. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239–245.
    1. Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries. J Am Geriatr Soc. 2012;60(7):1298–1303. doi: 10.1111/j.1532-5415.2012.04037.x.
    1. Poon I, Lal LS, Ford ME, Braun UK. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother. 2009;43(2):185–193. doi: 10.1345/aph.1L368.
    1. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45–50. doi: 10.2165/00129784-200808010-00006.
    1. Krousel-Wood M, Holt E, Joyce C, et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO) J Hypertens Feb. 2015;33(2):412–420. doi: 10.1097/HJH.0000000000000382.
    1. Stewart K, Mc Namara KP, George J. Challenges in measuring medication adherence: experiences from a controlled trial. Int J Clin Pharm. 2014;36(1):15–19. doi: 10.1007/s11096-013-9877-6.
    1. Schectman JM, Bovbjerg VE, Voss JD. Predictors of medication-refill adherence in an indigent rural population. Med Care. 2002;40(12):1294–1300. doi: 10.1097/00005650-200212000-00016.
    1. Han E, Suh DC, Lee SM, Jang S. The impact of medication adherence on health outcomes for chronic metabolic diseases: A retrospective cohort study. Res Social Adm Pharm. 2014;10(6):e87–98. doi: 10.1016/j.sapharm.2014.02.001.
    1. Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med. 2012;156(11):776–784. doi: 10.7326/0003-4819-156-11-201206050-00004.
    1. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885–892. doi: 10.2165/00002512-200825100-00008.
    1. GuildCare. MedScreen Programs. 2013; . Accessed 9 Feb 2017.
    1. Jackson KC, 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008;30(8):1558–1563. doi: 10.1016/j.clinthera.2008.08.010.
    1. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20(1):72–80. doi: 10.3122/jabfm.2007.01.060094.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa